Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Coppo

Showing results (111-120 of 199) with videos related to

Pageof 20
Sort By:
Research and Practice in Thrombosis and Haemostasis|September 2, 2024
Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpuraKaterina Pavenski, Marie Scully, Paul Coppo, et al.
Frontiers in Immunology|July 10, 2024
A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed/refractory AITLLaure Ricard, Pascale Cervera, Nicolas Stocker, et al.
Haematologica|November 2, 2020
Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpuraNuno A G Graça, Bogac Ercig, Leydi Carolina Velásquez Pereira, et al.
Kidney International Reports|April 14, 2025
Pilot Study of Diagnostic Performances of Vascular Biomarkers Soluble fms-Like Tyrosine Kinase and Placental Growth Factor in Scleroderma Renal CrisisAïcha Kante, Paul Legendre, Bérangère S Joly, et al.
The Lancet. Haematology|October 11, 2016
Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathyBérangère S Joly, Alain Stepanian, Thierry Leblanc, et al.
Journal of Nephrology|October 10, 2023
The challenging follow-up of pregnancy in women with known thrombotic thrombocytopenic purpura: a single-center experience of a preemptive management protocolAghiles Hamroun, Camille Prouteau, Rémi Lenain, et al.
Scandinavian Journal of Immunology|December 8, 2021
Overexpression of IgG2 in patients resembling IgG4-related disease with normal IgG4Mathilde Lecuit, Pierre Aucouturier, Aicha Abbas, et al.
Blood Advances|September 24, 2021
Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTPLaure De Waele, Alexandre Curie, Kadri Kangro, et al.
Blood Advances|April 21, 2021
Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysisFlora Peyvandi, Spero Cataland, Marie Scully, et al.
Haematologica|December 1, 2022
Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severityEdwige Tellier, Agnès Widemann, Raphaël Cauchois, et al.
Pageof 20

Showing results (111-120 of 199) with videos related to

Sort By:
Pageof 20
Research and Practice in Thrombosis and Haemostasis|September 2, 2024
Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpuraKaterina Pavenski, Marie Scully, Paul Coppo, et al.
Frontiers in Immunology|July 10, 2024
A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed/refractory AITLLaure Ricard, Pascale Cervera, Nicolas Stocker, et al.
Haematologica|November 2, 2020
Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpuraNuno A G Graça, Bogac Ercig, Leydi Carolina Velásquez Pereira, et al.
Kidney International Reports|April 14, 2025
Pilot Study of Diagnostic Performances of Vascular Biomarkers Soluble fms-Like Tyrosine Kinase and Placental Growth Factor in Scleroderma Renal CrisisAïcha Kante, Paul Legendre, Bérangère S Joly, et al.
The Lancet. Haematology|October 11, 2016
Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathyBérangère S Joly, Alain Stepanian, Thierry Leblanc, et al.
Journal of Nephrology|October 10, 2023
The challenging follow-up of pregnancy in women with known thrombotic thrombocytopenic purpura: a single-center experience of a preemptive management protocolAghiles Hamroun, Camille Prouteau, Rémi Lenain, et al.
Scandinavian Journal of Immunology|December 8, 2021
Overexpression of IgG2 in patients resembling IgG4-related disease with normal IgG4Mathilde Lecuit, Pierre Aucouturier, Aicha Abbas, et al.
Blood Advances|September 24, 2021
Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTPLaure De Waele, Alexandre Curie, Kadri Kangro, et al.
Blood Advances|April 21, 2021
Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysisFlora Peyvandi, Spero Cataland, Marie Scully, et al.
Haematologica|December 1, 2022
Immune-mediated thrombotic thrombocytopenic purpura plasma induces calcium- and IgG-dependent endothelial activation: correlations with disease severityEdwige Tellier, Agnès Widemann, Raphaël Cauchois, et al.
Pageof 20